Targeting of the WT1 91 –138 fragment to human dendritic cells improves leukemia-specific T-cell responses providing an alternative approach to WT1-based vaccination

In conclusion, our approach identifies four WT1 peptide-antibody fusion proteins with sufficient production and introduces an alternative vaccine that could be easily translated into clinical practice to improve WT1-directed antileukemia immune responses after allo-HSCT.

http://link.springer.com/10.1007/s00262-016-1938-y

Source: Cancer Immunology, Immunotherapy - November 27, 2016 Category: Cancer & Oncology Source Type: research